These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23771358)

  • 1. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
    Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
    J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
    Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
    Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
    Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
    ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
    Setoain X; López-Guillermo A; Ruiz A; Pons F
    Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
    [No Abstract]   [Full Text] [Related]  

  • 6. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
    Postema EJ; Oyen WJ; Boerman OC; Corstens FH
    J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
    Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
    Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
    Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
    Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
    Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
    Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
    Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
    Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
    Bello P; Almoguera MI; Pajares M; Olivas C; Lapeña L; Freire JM;
    Rev Esp Med Nucl; 2010; 29(1):50-2. PubMed ID: 19963305
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
    Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
    Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
    J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.